Oncology Central

Targeting CD8+ T-cell tolerance for cancer immunotherapy

0

In the final issue of Science in 2013, the American Association of Science recognized progress in the field of cancer immunotherapy as the ‘Breakthrough of the Year.’ The achievements were actually twofold, owing to the early success of genetically engineered chimeric antigen receptors (CAR) and to the mounting clinical triumphs achieved with checkpoint blockade antibodies.

To view restricted content, please:
Share:

Leave A Comment